ReviewAdvances in therapy2017
Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications.
Review in Advances in therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Immunosuppressive Therapies in Pulmonary Sarcoidosis: A Practical, Evidence-Based Review.Journal of clinical medicine · 2025Review
- Study on the gut microbiota, HPA, and cytokine levels in infantile spasms.Frontiers in immunology · 2024Article
- ActharClinical drug investigation · 2023Review
- A Narrative Review of Acthar Gel for the Treatment of Myositis.Rheumatology and therapy · 2023Review
- Trends and Costs Associated With the Diagnosis and Treatment of Infantile Spasms: A 10-Year Multicenter Retrospective Review.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022Article
- Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis.Drugs in context · 2022Article
- Real-World Treatment Patterns and Outcomes from an Electronic Medical Records Database for Patients with Rheumatoid Arthritis Treated with Repository Corticotropin Injection.Open access rheumatology : research and reviews · 2021Article
- Recent advances in the management of non-infectious posterior uveitis.International ophthalmology · 2020Review
- Study on the differentially expressed genes and signaling pathways in dermatomyositis using integrated bioinformatics method.Medicine · 2020Article
- Development and Study of Semi-Solid Preparations Containing the Model Substance Corticotropin (ACTH): Convenience Application in Neurodegenerative Diseases.Molecules (Basel, Switzerland) · 2020Article
- Management of repository corticotrophin injection therapy for pulmonary sarcoidosis: a Delphi study.European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Melanocortin Regulation of Inflammation.Frontiers in endocrinology · 2019Review
- Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin.JAMA network open · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRepository corticotropin injection (RCI; H.P. Acthar
methodsKey studies of clinical efficacy and healthcare utilization and cost from 1956 to 2016 are summarized.
resultsThe evidence supports the efficacy of RCI across the seven indications. RCI is effective as a first-line therapy for IS. For the other six conditions, RCI may improve clinical outcomes during exacerbations or when the condition is resistant to conventional treatments. Use of RCI is associated with reduced use of biologics, corticosteroids, and disease-modifying antirheumatic drugs. Initiation of RCI therapy in patients with IS, MS, RA, SLE, or DM/PM has been associated with lower post-therapy healthcare utilization and medical costs, including decreases in hospitalizations, hospital length of stay, outpatient visits, and emergency department visits.
conclusionThe evidence suggests that RCI may improve inflammatory and autoimmune disease control and patient quality of life, particularly in complex patients, and yield healthcare cost savings that demonstrate the medicine's value.
fundingMallinckrodt Pharmaceuticals Inc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.